SG Americas Securities LLC cut its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 47.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,447 shares of the biotechnology company's stock after selling 3,073 shares during the period. SG Americas Securities LLC's holdings in Repligen were worth $496,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of RGEN. UMB Bank n.a. raised its stake in Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock worth $33,000 after acquiring an additional 130 shares in the last quarter. Blue Trust Inc. increased its position in shares of Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 127 shares in the last quarter. Resources Management Corp CT ADV bought a new position in Repligen during the 3rd quarter valued at about $37,000. Quarry LP boosted its position in Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company's stock valued at $40,000 after buying an additional 239 shares in the last quarter. Finally, nVerses Capital LLC bought a new stake in Repligen during the third quarter worth about $45,000. Institutional investors own 97.64% of the company's stock.
Analyst Upgrades and Downgrades
RGEN has been the subject of a number of research analyst reports. Canaccord Genuity Group started coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a "hold" rating and a $165.00 target price for the company. Canaccord Genuity Group began coverage on Repligen in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective for the company. Wolfe Research initiated coverage on Repligen in a report on Thursday, November 14th. They set a "peer perform" rating on the stock. HC Wainwright cut their price target on Repligen from $240.00 to $180.00 and set a "buy" rating for the company in a report on Thursday, January 23rd. Finally, StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research report on Friday, January 3rd. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $184.73.
Check Out Our Latest Analysis on Repligen
Repligen Trading Up 1.2 %
NASDAQ RGEN traded up $1.91 during trading hours on Wednesday, hitting $161.93. The company's stock had a trading volume of 413,036 shares, compared to its average volume of 567,845. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13. The firm has a market capitalization of $9.07 billion, a P/E ratio of -437.64, a PEG ratio of 4.67 and a beta of 0.99. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock has a fifty day moving average of $155.02 and a 200 day moving average of $148.41.
Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts' consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same quarter in the prior year, the business posted $0.23 EPS. The firm's quarterly revenue was up 9.7% on a year-over-year basis. Equities research analysts forecast that Repligen Co. will post 1.54 earnings per share for the current fiscal year.
Repligen Profile
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
See Also
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
